This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Hanks GE , Buzydlowski J , Sause WT , Emami B , Rubin P , Parsons JA , Russell AH , Byhardt RW , Earle JD , Pilepich MV
Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06
International Journal of Radiation Oncology Biology Physics. 1998 Mar 1;40(4) :765-768
AbstractPurpose: This study was conducted to see what fraction of prostate cancer patients with biopsy-proven nodes are free of cancer 10 years after radiation treatment, Methods and Materials: RTOG protocol #75-06 included 90 patients with biopsy-proven pelvic nodal involvement treated with radiation. They have been continuously follow-up since treatment, When feasible, current prostate-specific antigen (PSA) levels have been solicited from patients clinically cancer-free (no evidence of disease, NED) at 10 years, to confirm cure, Results: The 10-year survival was 29%, the 10-year clinical NED survival 7%, PSA levels were obtained in 2 of 5 10-year clinical NED patients, they were both less than 0.8 ng/ml, The 2 proven cures were both clinical stage T-3, Gleason Score 6 and 8, and had 2 and 1 positive nodes, respectively, Multivariate analysis showed Gleason sum was significantly associated with clinical survival without disease, Conclusion: A small fraction of node-positive patients are cured at 10-year follow-up by radiation therapy (2 of 90 with PSA +3 of 90 by clinical endpoints), Innovative treatment programs should be directed at node-positive patients in an effort to improve the fraction cured. (C) 1998 Elsevier Science Inc.
NotesTimes Cited: 10 English Article ZC991 INT J RADIAT ONCOL BIOL PHYS